A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea

Cutis

Volumn 96, Issue 1, 2015, Pages 54-61

  Draelos, Zoe Diana ^a   Elewski, Boni E ^b   Harper, Julie C ^c   Sand, Meike ^d   Staedtler, Gerald ^d   Nkulikiyinka, Richard ^d   Shakery, Kaweh ^d  

^a DERMATOLOGY CONSULTING SERVICES   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Dermatology and Skin Care Center of Birmingham   (United States)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID;

ADULT; AGED; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; ROSACEA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84941116847     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
2. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysi-ological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16-25.
3. Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient's quality of life. Am Health Drug Benefits. 2013;6:348-354.
4. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69(6 suppl 1):S27-S35.
5. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 suppl 1):S15-S26.
6. Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime Rep. 2014;6:50.
7. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93:134-138.
8. Draelos ZD, Elewski B, Staedtler G, et al. Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis. 2013;92:306-317.
9. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975-980.
10. Mastrofrancesco A, Ottaviani M, Aspite N, et al. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARγ activation. Exp Dermatol. 2010;19:813-820.
11. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
12. Coda AB, Hata T, Miller J, et al. Cathelicidin, kalli-krein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69:570-577.
13. van Zuuren EJ, Kramer S F, Carter BR, et al. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol. 2011;165:760-781.
14. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
15. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008; 7:541-546.
16. Finacea [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2015.
17. Zhao Y, Jones SA, Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol. 2010;62:678-684.
18. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.
19. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4:771-788.
20. Jackson JM, Pelle M. Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance. J Drugs Dermatol. 2011;10:627-633.
21. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327-332.
22. Kircik LH, Bikowski JB. Vehicles matter: topical foam formulations. Practical Dermatology. January 2012(suppl):3-18.